China biotech RiboX reports first human data for circular RNA therapies

China biotech company RiboX has disclosed its initial human data on circular RNA therapeutics, marking the first clinical readout for this emerging platform.

The study represents a milestone for the circular RNA approach, which researchers hope will deliver more durable and potent treatments compared with conventional mRNA.

Investors have already poured billions into Boston-area startups pursuing next‑generation RNA technologies, and RiboX’s data adds a new contender to the field.

While detailed efficacy results were not provided, the announcement underscores growing interest in alternative RNA modalities for future drug development.